Generic placeholder image

Inflammation & Allergy - Drug Targets (Discontinued)

Editor-in-Chief

ISSN (Print): 1871-5281
ISSN (Online): 2212-4055

Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a New Biomarker for Non – Acute Kidney Injury (AKI) Diseases

Author(s): Janice Giasson, Guo Hua Li and Yu Chen

Volume 10, Issue 4, 2011

Page: [272 - 282] Pages: 11

DOI: 10.2174/187152811796117753

Price: $65

Abstract

Neutrophil gelatinase-associated lipocalin, or NGAL, an acute phase protein, is part of the lipocalin family. NGAL is highly induced in inflammatory conditions and ischemia, and is a critical component of innate immunity to bacterial infection. Recently, NGAL has been proven as an emerging biomarker for predicting acute kidney injury (AKI). Meanwhile, numerous studies have also demonstrated that NGAL may be a potential biomarker for the diagnosis, prediction, prevention, and prognosis of non-AKI diseases such as chronic kidney diseases, vascular disorders, cancer, preeclampsia, and allergies. This article systematically reviews the clinical utilities of NGAL as a new biomarker for non - AKI diseases.

Keywords: NGAL, biomarker, non-AKI diseases, diagnosis, Acute kidney injury, Anti-neutrophilic cytoplasmic auto-antibodies, Chronic kidney disease, Cardiovascular Disorders, Neutrophil Gelatinase-Associated Lipocalin, vascular disorders, preeclampsia


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy